Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Total Liabilities (2019 - 2025)

Vivos Therapeutics' Total Liabilities history spans 7 years, with the latest figure at $26.7 million for Q4 2025.

  • Quarterly results put Total Liabilities at $26.7 million for Q4 2025, up 264.28% from a year ago — trailing twelve months through Dec 2025 was $26.7 million (up 264.28% YoY), and the annual figure for FY2025 was $26.7 million, up 264.28%.
  • Total Liabilities for Q4 2025 was $26.7 million at Vivos Therapeutics, up from $23.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $26.7 million in Q4 2025 to a low of $6.9 million in Q1 2025.
  • The 5-year median for Total Liabilities is $9.5 million (2022), against an average of $11.3 million.
  • The sharpest move saw Total Liabilities surged 403.67% in 2021, then crashed 38.51% in 2025.
  • Year by year, Total Liabilities stood at $8.2 million in 2021, then increased by 9.44% to $8.9 million in 2022, then increased by 15.7% to $10.3 million in 2023, then fell by 28.97% to $7.3 million in 2024, then skyrocketed by 264.28% to $26.7 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $26.7 million, $23.1 million, and $21.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.